GLP-1 Drug Popularity Creates $5 Billion Inventory Risk for Fashion Retailers
Increased adoption of weight-loss medications is leading to a surplus of plus-size clothing, forcing retailers to reassess inventory strategies.
The widespread use of GLP-1 medications, such as Ozempic and Wegovy, is creating a significant inventory challenge for the fashion industry, with an estimated $5 billion in clothing at risk of becoming obsolete. These drugs, prescribed for Type 2 diabetes and weight management, are contributing to rapid weight loss among users, altering demand for clothing sizes and causing a surplus of larger sizes.
Analysts at Impact Analytics, a retail and AI-innovation consultancy, project that if current adoption trends for GLP-1 drugs continue, over 400 million apparel units annually could be misaligned by 2027. This misalignment represents a potential loss of approximately $5 billion in retail capital and margin. The study highlights a societal shift towards smaller clothing sizes, impacting sales and increasing returns for sizes large (L), extra large (XL), and larger.
Data indicates a notable decline in sales for apparel sizes XL and above. Between 2024 and 2025, sales in these sizes dropped by 9%. For women's clothing, sales in sizes XS and S increased from 34% to 39% between 2022 and 2024, while L and XL sizes decreased from 33% to 31% during the same period. Menswear also saw a reduction in larger-sized tops sales, shrinking from 33% to 30%, and pants from 40% to 38% over the two years.
Retailers are also experiencing a surge in returns for larger-sized garments. Women's bottoms, including jeans and slacks, saw a rise in returns from 12.3% to 15.2% in recent years. This increase in returns is described by experts as a "lagging financial signal" that precedes the clear visibility of aged inventory or markdown performance. The current trend suggests that stocking larger sizes in 2026 and 2027 could lead to overstocked shelves with outdated inventory, potentially causing "two years of distortion" for retailers.
Approximately 12% of Americans are reportedly using GLP-1s for weight and health management. In New York City, about 75% of women are said to be on non-diabetic GLP-1 prescriptions, leading the nation in this trend.
To mitigate these financial risks, experts advise fashion retailers to recalibrate their inventory strategies. Instead of relying on outdated demand metrics, companies should adjust their sizing based on the evolving trends influenced by GLP-1 usage. This proactive approach is crucial to prevent further compounding of financial risks before the next buying cycle locks in potentially obsolete assumptions. The industry is urged to interpret the increase in returns not as mere operational friction but as a leading indicator of significant shifts in size-curve demand.